SK285863B6 - Kombinovaná farmaceutická kompozícia obsahujúca AT1-antagonistu valsartan a amlodipín - Google Patents

Kombinovaná farmaceutická kompozícia obsahujúca AT1-antagonistu valsartan a amlodipín Download PDF

Info

Publication number: SK285863B6
Authority: SK; Slovakia
Prior art keywords: valsartan; amlodipine; pharmaceutically acceptable; diabetic; acceptable salt
Prior art date: 1998-07-10

Application number

SK31-2001A

Other languages

English (en)

Slovak (sk)

Other versions

SK312001A3 (en

Inventor

Gasparo Marc De

Randy Lee Webb

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-10

Filing date

1999-07-09

Publication date

2007-10-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22352165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK285863(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-07-09 Application filed by Novartis Ag filed Critical Novartis Ag

2001-06-11 Publication of SK312001A3 publication Critical patent/SK312001A3/sk

2007-10-04 Publication of SK285863B6 publication Critical patent/SK285863B6/sk

Links

239000000203 mixture Substances 0.000 title abstract description 7
239000000400 angiotensin II type 1 receptor blocker Substances 0.000 title abstract description 3
229940043102 valsartan and amlodipine Drugs 0.000 title description 4
239000004072 C09CA03 - Valsartan Substances 0.000 claims abstract description 30
229960004699 valsartan Drugs 0.000 claims abstract description 30
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims abstract description 30
150000003839 salts Chemical class 0.000 claims abstract description 27
229960000528 amlodipine Drugs 0.000 claims abstract description 16
239000003937 drug carrier Substances 0.000 claims abstract description 8
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims abstract 4
239000008194 pharmaceutical composition Substances 0.000 claims description 11
239000005557 antagonist Substances 0.000 claims description 9
229940066469 amlodipine 5 mg Drugs 0.000 claims description 2
239000007916 tablet composition Substances 0.000 claims description 2
229940102034 valsartan 80 mg Drugs 0.000 claims description 2
206010020772 Hypertension Diseases 0.000 abstract description 25
206010012601 diabetes mellitus Diseases 0.000 description 32
229940127291 Calcium channel antagonist Drugs 0.000 description 19
241000700159 Rattus Species 0.000 description 19
239000000480 calcium channel blocker Substances 0.000 description 19
238000011699 spontaneously hypertensive rat Methods 0.000 description 15
ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 13
208000007342 Diabetic Nephropathies Diseases 0.000 description 10
206010019280 Heart failures Diseases 0.000 description 10
230000036772 blood pressure Effects 0.000 description 10
229940079593 drug Drugs 0.000 description 10
239000003814 drug Substances 0.000 description 10
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 9
230000000694 effects Effects 0.000 description 9
208000001072 type 2 diabetes mellitus Diseases 0.000 description 9
229960001722 verapamil Drugs 0.000 description 9
206010002383 Angina Pectoris Diseases 0.000 description 8
208000001647 Renal Insufficiency Diseases 0.000 description 7
239000004480 active ingredient Substances 0.000 description 7
230000000747 cardiac effect Effects 0.000 description 7
208000033679 diabetic kidney disease Diseases 0.000 description 7
201000006370 kidney failure Diseases 0.000 description 7
230000004083 survival effect Effects 0.000 description 7
208000019553 vascular disease Diseases 0.000 description 7
-1 1-carboxy-2-methylprop-1-yl Chemical group 0.000 description 6
238000002648 combination therapy Methods 0.000 description 6
239000003651 drinking water Substances 0.000 description 6
235000020188 drinking water Nutrition 0.000 description 6
230000001631 hypertensive effect Effects 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
201000001320 Atherosclerosis Diseases 0.000 description 5
206010007559 Cardiac failure congestive Diseases 0.000 description 5
208000006011 Stroke Diseases 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
208000017169 kidney disease Diseases 0.000 description 5
208000010125 myocardial infarction Diseases 0.000 description 5
201000001474 proteinuria Diseases 0.000 description 5
208000024827 Alzheimer disease Diseases 0.000 description 4
102000005862 Angiotensin II Human genes 0.000 description 4
101800000733 Angiotensin-2 Proteins 0.000 description 4
206010012689 Diabetic retinopathy Diseases 0.000 description 4
206010018364 Glomerulonephritis Diseases 0.000 description 4
206010020571 Hyperaldosteronism Diseases 0.000 description 4
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 4
206010049694 Left Ventricular Dysfunction Diseases 0.000 description 4
206010039710 Scleroderma Diseases 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
229950006323 angiotensin ii Drugs 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000037396 body weight Effects 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
206010061989 glomerulosclerosis Diseases 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
208000002815 pulmonary hypertension Diseases 0.000 description 4
239000003826 tablet Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
230000002792 vascular Effects 0.000 description 4
206010003658 Atrial Fibrillation Diseases 0.000 description 3
208000007530 Essential hypertension Diseases 0.000 description 3
208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
208000019695 Migraine disease Diseases 0.000 description 3
208000003782 Raynaud disease Diseases 0.000 description 3
208000012322 Raynaud phenomenon Diseases 0.000 description 3
206010039808 Secondary aldosteronism Diseases 0.000 description 3
230000009471 action Effects 0.000 description 3
230000003276 anti-hypertensive effect Effects 0.000 description 3
229940030600 antihypertensive agent Drugs 0.000 description 3
239000002220 antihypertensive agent Substances 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
208000010877 cognitive disease Diseases 0.000 description 3
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 3
229960004166 diltiazem Drugs 0.000 description 3
201000010099 disease Diseases 0.000 description 3
230000002526 effect on cardiovascular system Effects 0.000 description 3
206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
206010027599 migraine Diseases 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
230000002265 prevention Effects 0.000 description 3
201000009395 primary hyperaldosteronism Diseases 0.000 description 3
230000002685 pulmonary effect Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000002861 ventricular Effects 0.000 description 3
HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 2
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
229930182837 (R)-adrenaline Natural products 0.000 description 2
PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 2
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 2
NMKSAYKQLCHXDK-UHFFFAOYSA-N 3,3-diphenyl-N-(1-phenylethyl)-1-propanamine Chemical compound C=1C=CC=CC=1C(C)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NMKSAYKQLCHXDK-UHFFFAOYSA-N 0.000 description 2
UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 2
229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
206010003662 Atrial flutter Diseases 0.000 description 2
208000032781 Diabetic cardiomyopathy Diseases 0.000 description 2
206010048554 Endothelial dysfunction Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 description 2
ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 2
GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
206010042434 Sudden death Diseases 0.000 description 2
206010042600 Supraventricular arrhythmias Diseases 0.000 description 2
206010047281 Ventricular arrhythmia Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000004872 arterial blood pressure Effects 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000008694 endothelial dysfunction Effects 0.000 description 2
229960005139 epinephrine Drugs 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
229960002602 fendiline Drugs 0.000 description 2
SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 2
229960000326 flunarizine Drugs 0.000 description 2
238000009472 formulation Methods 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
229960004427 isradipine Drugs 0.000 description 2
210000005240 left ventricle Anatomy 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229960001783 nicardipine Drugs 0.000 description 2
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
229960001597 nifedipine Drugs 0.000 description 2
229960000715 nimodipine Drugs 0.000 description 2
229960005425 nitrendipine Drugs 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
238000005303 weighing Methods 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
SVJMLYUFVDMUHP-XIFFEERXSA-N (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid O5-[3-(4,4-diphenyl-1-piperidinyl)propyl] ester O3-methyl ester Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)OCCCN2CCC(CC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=CC([N+]([O-])=O)=C1 SVJMLYUFVDMUHP-XIFFEERXSA-N 0.000 description 1
FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 1
RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
101150059573 AGTR1 gene Proteins 0.000 description 1
206010001580 Albuminuria Diseases 0.000 description 1
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
229940123413 Angiotensin II antagonist Drugs 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
229920003084 Avicel® PH-102 Polymers 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 description 1
206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
ZROUQTNYPCANTN-UHFFFAOYSA-N Tiapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC1(C=2C=C(OC)C(OC)=CC=2)S(=O)(=O)CCCS1(=O)=O ZROUQTNYPCANTN-UHFFFAOYSA-N 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
DOQPXTMNIUCOSY-UHFFFAOYSA-N [4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-[2-(3,4-dimethoxyphenyl)ethyl]-methylazanium;chloride Chemical compound [H+].[Cl-].C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 DOQPXTMNIUCOSY-UHFFFAOYSA-N 0.000 description 1
210000003815 abdominal wall Anatomy 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
229960002478 aldosterone Drugs 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229960004005 amlodipine besylate Drugs 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
PHFDAOXXIZOUIX-UHFFFAOYSA-N anipamil Chemical compound C=1C=CC(OC)=CC=1C(CCCCCCCCCCCC)(C#N)CCCN(C)CCC1=CC=CC(OC)=C1 PHFDAOXXIZOUIX-UHFFFAOYSA-N 0.000 description 1
229950011530 anipamil Drugs 0.000 description 1
230000000489 anti-atherogenic effect Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
230000001746 atrial effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
229960005316 diltiazem hydrochloride Drugs 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
230000008753 endothelial function Effects 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
229960003580 felodipine Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
238000003304 gavage Methods 0.000 description 1
239000008187 granular material Substances 0.000 description 1
210000002837 heart atrium Anatomy 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
229960004340 lacidipine Drugs 0.000 description 1
GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
238000012792 lyophilization process Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000000034 method Methods 0.000 description 1
229960004438 mibefradil Drugs 0.000 description 1
229960002439 mibefradil dihydrochloride Drugs 0.000 description 1
238000013508 migration Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000000465 moulding Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
201000009925 nephrosclerosis Diseases 0.000 description 1
229960002289 nicardipine hydrochloride Drugs 0.000 description 1
AIKVCUNQWYTVTO-UHFFFAOYSA-N nicardipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 AIKVCUNQWYTVTO-UHFFFAOYSA-N 0.000 description 1
229950010800 niguldipine Drugs 0.000 description 1
VZWXXKDFACOXNT-UHFFFAOYSA-N niludipine Chemical compound CCCOCCOC(=O)C1=C(C)NC(C)=C(C(=O)OCCOCCC)C1C1=CC=CC([N+]([O-])=O)=C1 VZWXXKDFACOXNT-UHFFFAOYSA-N 0.000 description 1
229950000109 niludipine Drugs 0.000 description 1
239000001272 nitrous oxide Substances 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000008816 organ damage Effects 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
230000036581 peripheral resistance Effects 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
229960001989 prenylamine Drugs 0.000 description 1
208000037920 primary disease Diseases 0.000 description 1
201000008312 primary pulmonary hypertension Diseases 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000029865 regulation of blood pressure Effects 0.000 description 1
210000005241 right ventricle Anatomy 0.000 description 1
208000037812 secondary pulmonary hypertension Diseases 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
210000002820 sympathetic nervous system Anatomy 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
229950003137 tiapamil Drugs 0.000 description 1
230000003639 vasoconstrictive effect Effects 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229960000881 verapamil hydrochloride Drugs 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
210000003368 zona glomerulosa Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Fats And Perfumes (AREA)
Hydrogenated Pyridines (AREA)

SK31-2001A 1998-07-10 1999-07-09 Kombinovaná farmaceutická kompozícia obsahujúca AT1-antagonistu valsartan a amlodipín SK285863B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11389398A	1998-07-10	1998-07-10
PCT/EP1999/004842 WO2000002543A2 (fr)	1998-07-10	1999-07-09	Methode de traitement et composition pharmaceutique

Publications (2)

Publication Number	Publication Date
SK312001A3 SK312001A3 (en)	2001-06-11
SK285863B6 true SK285863B6 (sk)	2007-10-04

Family

ID=22352165

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK31-2001A SK285863B6 (sk)	1998-07-10	1999-07-09	Kombinovaná farmaceutická kompozícia obsahujúca AT1-antagonistu valsartan a amlodipín

Country Status (31)

Country	Link
EP (3)	EP1870098A3 (fr)
JP (1)	JP2002520274A (fr)
KR (2)	KR20040078140A (fr)
CN (2)	CN1733307A (fr)
AT (1)	ATE371448T1 (fr)
AU (1)	AU753486B2 (fr)
BE (1)	BE2016C011I2 (fr)
BR (1)	BR9912021A (fr)
CA (2)	CA2678722C (fr)
CY (4)	CY1107779T1 (fr)
CZ (2)	CZ304359B6 (fr)
DE (2)	DE122007000055I1 (fr)
DK (2)	DK2322174T3 (fr)
ES (2)	ES2289814T3 (fr)
FR (1)	FR16C0008I2 (fr)
HU (1)	HU229383B1 (fr)
ID (1)	ID27664A (fr)
IL (3)	IL140665A0 (fr)
LU (2)	LU91358I2 (fr)
NL (2)	NL300290I2 (fr)
NO (2)	NO331802B1 (fr)
NZ (2)	NZ509260A (fr)
PL (1)	PL194604B1 (fr)
PT (2)	PT1096932E (fr)
RU (3)	RU2243768C2 (fr)
SG (1)	SG142116A1 (fr)
SI (2)	SI2322174T1 (fr)
SK (1)	SK285863B6 (fr)
TR (1)	TR200100062T2 (fr)
WO (1)	WO2000002543A2 (fr)
ZA (1)	ZA200100232B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2289814T3 (es)	1998-07-10	2008-02-01	Novartis Pharma Ag	Combinacion antihipertensiva de valsartan y bloqueador de canales del calcio.
KR100646716B1 (ko)	1998-12-23	2006-11-17	노파르티스 아게	Ａｔ-1 또는 ａｔ-2 수용체의 증가와 관련된 질환의치료에 있어서 ａｔ-1 수용체 길항제 또는 ａｔ-2 수용체조절제의 용도
WO2000066161A1 (fr)	1999-04-28	2000-11-09	Takeda Chemical Industries, Ltd.	Preventifs / remedes / inhibiteurs de progression pour retinopathie simplex ou retinopathie preproliferante
EP1197226B1 (fr) *	1999-07-21	2007-11-21	Takeda Pharmaceutical Company Limited	Agents destines a ameliorer les troubles causes par une insuffisance cerebrovasculaire et a inhiber leur evolution
SE9903028D0 (sv) *	1999-08-27	1999-08-27	Astra Ab	New use
HUP0203326A3 (en)	1999-08-30	2003-04-28	Sanofi Aventis Deutschland	Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
WO2001062741A1 (fr) *	2000-02-25	2001-08-30	South Alabama Medical Science Foundation	Derives de tetrahydronaphtalene et leur utilisation
WO2001062740A1 (fr) *	2000-02-25	2001-08-30	South Alabama Medical Science Foundation	Analogues de mibefradil et leur utilisation
KR20020089437A (ko) *	2000-04-12	2002-11-29	노파르티스 아게	유기 화합물의 배합
DE10018401A1 (de) *	2000-04-13	2001-10-25	Boehringer Ingelheim Pharma	Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
US20060089389A1 (en)	2000-08-22	2006-04-27	Malcolm Allison	Combination
PE20020617A1 (es) *	2000-08-22	2002-08-05	Novartis Ag	Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
WO2002053147A1 (fr) *	2000-12-29	2002-07-11	Osmotica Corp.	Composition pharmaceutique destinee au traitement de la maladie cerebrovasculaire cognitive
ITMI20010129A1 (it) *	2001-01-25	2002-07-25	Pharmacia & Upjohn Spa	Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
US20040266836A1 (en) *	2001-10-18	2004-12-30	Peter Buhlmayer	Organic compounds
US20030180712A1 (en) *	2002-03-20	2003-09-25	Biostratum Ab	Inhibition of the beta3 subunit of L-type Ca2+ channels
EG24716A (en) *	2002-05-17	2010-06-07	Novartis Ag	Combination of organic compounds
US20040138306A1 (en)	2002-07-25	2004-07-15	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
DE10335027A1 (de) *	2003-07-31	2005-02-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von Angiotensin II Rezeptor Antagonisten
SE0300988D0 (sv) *	2003-04-03	2003-04-03	Astrazeneca Ab	New use
WO2004110354A2 (fr)	2003-05-15	2004-12-23	Roskamp Research, Llc	Methode de reduction d'un depot amyloide, neurotoxicite amyloide et microgliose
MXPA05012299A (es) *	2003-05-16	2006-01-30	Novartis Ag	Composicion farmaceutica que comprende valsartan.
RU2255740C2 (ru) *	2003-07-02	2005-07-10	Научно-исследовательский институт кардиологии Томского научного центра СО РАМН	Способ подбора дозы дилтиазема для лечения больных постинфарктным кардиосклерозом с недостаточностью кровообращения 2 функционального класса
US20050065094A1 (en)	2003-09-05	2005-03-24	Boehringer Ingelheim International Gmbh	Use of telmisartan for the prevention and treatment of vascular headache
WO2005053687A1 (fr) *	2003-11-25	2005-06-16	Novartis Ag	Combinaison de composes organiques
US20050209288A1 (en) *	2004-01-12	2005-09-22	Grogan Donna R	Compositions comprising (S)-amlodipine malate and an angiotensin receptor blocker and methods of their use
CN100364532C (zh) *	2004-09-30	2008-01-30	江苏恒瑞医药股份有限公司	包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物
ES2374716T3 (es)	2005-04-15	2012-02-21	Research & Innovation S.P.A.	Método para prevenir, retrasar o revertir la deposición anormal de amiloide.
GT200600371A (es) *	2005-08-17	2007-03-21		Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
GB0520405D0 (en) *	2005-10-07	2005-11-16	Imp College Innovations Ltd	Biological agents and method
CA2626682A1 (fr) *	2005-11-08	2007-05-18	Novartis Ag	Combinaison de composes organiques pour le traitement des maladies cardiovasculaires
AR057882A1 (es)	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
RU2329805C2 (ru) *	2006-08-28	2008-07-27	Илья Николаевич Медведев	Способ стабилизации эндотелиальной выстилки сосудов у больных метаболическим синдромом
KR100888131B1 (ko) *	2006-10-10	2009-03-11	한올제약주식회사	시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
RU2338527C1 (ru) *	2007-02-26	2008-11-20	Илья Николаевич Медведев	Способ коррекции высокой эндотелиоцитемии у лиц с метаболическим синдромом
CN101883564B (zh)	2007-10-05	2013-10-16	阿尔茨海默病学会美国公司	使用(-)-尼伐地平对映体减少淀粉状蛋白沉积、淀粉状蛋白神经毒性和小神经胶质增生的方法
CN101433536A (zh) *	2007-11-12	2009-05-20	北京瑞康医药技术有限公司	含有烟酸氨氯地平和沙坦类药物的治疗组合物
WO2009084003A1 (fr) *	2007-12-31	2009-07-09	Lupin Limited	Compositions pharmaceutiques d'amlodipine et de valsartan
WO2010006103A1 (fr) *	2008-07-10	2010-01-14	Ore Pharmaceuticals Inc.	Procédé d’amplification de la cognition ou d’inhibition du déclin de la cognition
RU2382644C1 (ru) *	2008-11-05	2010-02-27	Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию"	Способ коррекции гипертрофии левого желудочка у больных ибс в сочетании с гипертонической болезнью
RU2398581C1 (ru) *	2009-05-28	2010-09-10	Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс Федерального агентства по высокотехнологичной медицинской помощи (ФГУ РКНПК Росмедтехнологий)	Способ лечения больных гипертрофической кардиомиопатией
WO2011102702A2 (fr)	2010-02-16	2011-08-25	Krka, D. D., Novo Mesto	Procédé pour la préparation de formes posologiques solides orales comprenant du valsartan
IT1400309B1 (it)	2010-05-10	2013-05-24	Menarini Int Operations Lu Sa	Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
UA110244C2 (en) *	2011-04-12	2015-12-10	Boryung Pharm	Antihypertensive pharmaceutical composition
AR089646A1 (es)	2011-08-12	2014-09-10	Boehringer Ingelheim Vetmed	Inhibidores de corrientes funny (if) para utilizar en un metodo de tratamiento y prevencion de la insuficiencia cardiaca en felinos
JPWO2013147137A1 (ja) *	2012-03-30	2015-12-14	味の素株式会社	心不全の治療剤
CZ2013783A3 (cs)	2013-10-08	2015-04-15	Zentiva, K. S	Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
WO2016073179A2 (fr) *	2014-10-23	2016-05-12	The Trustees Of The University Of Pennsylvania	Nouvelle chronothérapie basée sur les rythmes circadiens
RU2616213C2 (ru) *	2015-07-10	2017-04-13	Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ЮУГМУ Минздрава России)	Способ коррекции дисфункции факторов врожденного и адаптивного иммунитета при хронической почечной недостаточности в эксперименте
PL3368080T3 (pl) *	2015-10-31	2023-09-11	Io Therapeutics, Inc.	Leczenie zaburzeń układu nerwowego z zastosowaniem kombinacji agonistów rxr i hormonów tarczycy
CN105287550A (zh) *	2015-11-19	2016-02-03	哈尔滨圣吉药业股份有限公司	一种缬沙坦/非洛地平复方制剂及其制备方法
EP4136103A4 (fr) *	2020-04-17	2024-05-15	HB Biotech, Inc.	Compositions et méthodes de traitement de troubles neuropsychiatriques
US20240299405A1 (en) *	2020-05-28	2024-09-12	Hangzhou Qian Biotechnology Ltd	Application of atp potassium channel modifier in preparation of anti-diabetic nephropathy drug

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4654372A (en) *	1986-01-10	1987-03-31	Warner-Lambert Company	Method for using verapamil for treating stroke
GB8608335D0 (en)	1986-04-04	1986-05-08	Pfizer Ltd	Pharmaceutically acceptable salts
DE122010000024I1 (de) *	1990-02-19	2010-07-08	Novartis Ag	Acylverbindungen
NZ242724A (en)	1991-05-15	1994-09-27	Du Pont	Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
US5492904A (en) *	1991-05-15	1996-02-20	E. I. Du Pont De Nemours And Company	Composition of angiotensin-II receptor antagonists and calcium channel blockers
WO1993017682A1 (fr) *	1992-03-04	1993-09-16	Abbott Laboratories	Antagonistes des recepteurs de l'angiotensine ii
ATE157672T1 (de) *	1992-07-27	1997-09-15	Pfizer	Calcium-kanal blockierende polypeptide aus agelenopsis aperta
US5264447A (en) *	1992-09-01	1993-11-23	Merck & Co., Inc.	Angiotensin II antagonist
CA2125251C (fr) *	1993-06-07	2005-04-26	Yoshiyuki Inada	Composition pharmaceutique pour le traitement des affections mediees par l'angiotensine ii
US5721263A (en) *	1993-06-07	1998-02-24	Takeda Chemical Industries, Ltd.	Pharmaceutical composition for angiotensin II-mediated diseases
ES2154277T3 (es) *	1993-07-15	2001-04-01	Hoffmann La Roche	Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina.
ATE300287T1 (de) *	1994-02-08	2005-08-15	Novartis Pharma Gmbh	Behandlung von normaldruckglaukom mit valsartan
EP0750500A1 (fr) *	1994-03-17	1997-01-02	Ciba-Geigy Ag	Traitement de la nephropathie diabetique a l'aide de valsartan
GB9613470D0 (en) *	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
ES2289814T3 (es)	1998-07-10	2008-02-01	Novartis Pharma Ag	Combinacion antihipertensiva de valsartan y bloqueador de canales del calcio.

1999
- 1999-07-09 ES ES99934647T patent/ES2289814T3/es not_active Expired - Lifetime
- 1999-07-09 NZ NZ509260A patent/NZ509260A/en not_active IP Right Cessation
- 1999-07-09 ID IDW20010051A patent/ID27664A/id unknown
- 1999-07-09 SI SI9931078T patent/SI2322174T1/sl unknown
- 1999-07-09 EP EP07105179A patent/EP1870098A3/fr not_active Withdrawn
- 1999-07-09 WO PCT/EP1999/004842 patent/WO2000002543A2/fr not_active Ceased
- 1999-07-09 DE DE200712000055 patent/DE122007000055I1/de active Pending
- 1999-07-09 CA CA2678722A patent/CA2678722C/fr not_active Expired - Lifetime
- 1999-07-09 CA CA002336822A patent/CA2336822C/fr not_active Expired - Lifetime
- 1999-07-09 EP EP99934647A patent/EP1096932B1/fr not_active Revoked
- 1999-07-09 CZ CZ2007-647A patent/CZ304359B6/cs not_active IP Right Cessation
- 1999-07-09 BR BR9912021-6A patent/BR9912021A/pt not_active IP Right Cessation
- 1999-07-09 IL IL14066599A patent/IL140665A0/xx unknown
- 1999-07-09 PL PL99345897A patent/PL194604B1/pl unknown
- 1999-07-09 AU AU50349/99A patent/AU753486B2/en not_active Expired
- 1999-07-09 KR KR10-2004-7011566A patent/KR20040078140A/ko not_active Ceased
- 1999-07-09 ES ES10177093.1T patent/ES2552639T3/es not_active Expired - Lifetime
- 1999-07-09 AT AT99934647T patent/ATE371448T1/de active
- 1999-07-09 HU HU0102828A patent/HU229383B1/hu active Protection Beyond IP Right Term
- 1999-07-09 RU RU2001102585/15K patent/RU2243768C2/ru active
- 1999-07-09 SK SK31-2001A patent/SK285863B6/sk not_active IP Right Cessation
- 1999-07-09 NZ NZ527598A patent/NZ527598A/xx not_active IP Right Cessation
- 1999-07-09 JP JP2000558803A patent/JP2002520274A/ja active Pending
- 1999-07-09 DE DE69936992T patent/DE69936992T2/de not_active Expired - Lifetime
- 1999-07-09 CZ CZ20010087A patent/CZ299429B6/cs unknown
- 1999-07-09 RU RU2001102585/15A patent/RU2450813C2/ru active Protection Beyond IP Right Term
- 1999-07-09 PT PT99934647T patent/PT1096932E/pt unknown
- 1999-07-09 TR TR2001/00062T patent/TR200100062T2/xx unknown
- 1999-07-09 KR KR1020017000323A patent/KR100550167B1/ko not_active Expired - Fee Related
- 1999-07-09 EP EP10177093.1A patent/EP2322174B1/fr not_active Revoked
- 1999-07-09 DK DK10177093.1T patent/DK2322174T3/en active
- 1999-07-09 CN CNA200510072738XA patent/CN1733307A/zh active Pending
- 1999-07-09 SG SG200300082-5A patent/SG142116A1/en unknown
- 1999-07-09 PT PT101770931T patent/PT2322174E/pt unknown
- 1999-07-09 DK DK99934647T patent/DK1096932T3/da active
- 1999-07-09 CN CNB998097764A patent/CN1234357C/zh not_active Expired - Lifetime
- 1999-07-09 SI SI9930996T patent/SI1096932T1/sl unknown
2001
- 2001-01-01 IL IL140665A patent/IL140665A/en unknown
- 2001-01-08 NO NO20010113A patent/NO331802B1/no not_active IP Right Cessation
- 2001-01-09 ZA ZA200100232A patent/ZA200100232B/en unknown
2007
- 2007-09-06 LU LU91358C patent/LU91358I2/fr unknown
- 2007-09-10 NL NL300290C patent/NL300290I2/nl unknown
- 2007-10-25 CY CY20071101384T patent/CY1107779T1/el unknown
- 2007-10-30 CY CY200700026C patent/CY2007026I2/el unknown
2011
- 2011-07-04 IL IL213926A patent/IL213926A0/en unknown
2012
- 2012-03-20 RU RU2012110522/15A patent/RU2012110522A/ru unknown
- 2012-07-03 NO NO2012013C patent/NO2012013I2/no unknown
2015
- 2015-10-06 CY CY20151100890T patent/CY1116770T1/el unknown
2016
- 2016-03-07 CY CY2016006C patent/CY2016006I2/el unknown
- 2016-03-07 NL NL300800C patent/NL300800I2/nl unknown
- 2016-03-07 BE BE2016C011C patent/BE2016C011I2/nl unknown
- 2016-03-07 FR FR16C0008C patent/FR16C0008I2/fr active Active
- 2016-03-07 LU LU92992C patent/LU92992I2/fr unknown

Also Published As

Publication number	Publication date
CY2016006I1 (el)	2016-10-05
IL213926A0 (en)	2011-07-31
RU2243768C2 (ru)	2005-01-10
FR16C0008I2 (fr)	2018-06-08
DK2322174T3 (en)	2015-10-12
SG142116A1 (en)	2008-05-28
EP2322174A3 (fr)	2011-07-27
ES2289814T3 (es)	2008-02-01
HUP0102828A2 (hu)	2002-04-29
EP1096932B1 (fr)	2007-08-29
EP1870098A3 (fr)	2010-07-07
NZ527598A (en)	2005-04-29
NO2012013I1 (no)	2012-07-30
HK1036758A1 (en)	2002-01-18
HK1152897A1 (en)	2012-03-16
NL300290I1 (fr)	2007-11-01
JP2002520274A (ja)	2002-07-09
DE69936992T2 (de)	2008-03-06
SI1096932T1 (sl)	2008-04-30
CN1312715A (zh)	2001-09-12
PT2322174E (pt)	2015-10-27
CN1733307A (zh)	2006-02-15
CA2336822C (fr)	2009-11-17
RU2450813C2 (ru)	2012-05-20
NO20010113D0 (no)	2001-01-08
TR200100062T2 (tr)	2001-06-21
SI2322174T1 (sl)	2015-12-31
IL140665A0 (en)	2002-02-10
CA2678722C (fr)	2013-08-27
ID27664A (id)	2001-04-19
KR20040078140A (ko)	2004-09-08
WO2000002543A3 (fr)	2000-06-29
EP2322174A2 (fr)	2011-05-18
CN1234357C (zh)	2006-01-04
ATE371448T1 (de)	2007-09-15
PL194604B1 (pl)	2007-06-29
CY1116770T1 (el)	2016-10-05
CA2678722A1 (fr)	2000-01-20
CZ200187A3 (en)	2001-05-16
CY2007026I1 (el)	2009-11-04
NO331802B1 (no)	2012-04-10
CA2336822A1 (fr)	2000-01-20
BR9912021A (pt)	2001-04-03
NO20010113L (no)	2001-03-09
BE2016C011I2 (fr)	2018-12-04
DE69936992D1 (de)	2007-10-11
AU753486B2 (en)	2002-10-17
EP2322174B1 (fr)	2015-09-23
KR100550167B1 (ko)	2006-02-08
LU91358I2 (fr)	2007-11-06
CY2016006I2 (el)	2016-10-05
NL300290I2 (nl)	2008-11-03
LU92992I2 (fr)	2016-05-09
PT1096932E (pt)	2007-09-21
CZ299429B6 (cs)	2008-07-23
FR16C0008I1 (fr)	2016-04-15
EP1096932A2 (fr)	2001-05-09
DE122007000055I1 (de)	2007-12-13
KR20010079517A (ko)	2001-08-22
IL140665A (en)	2012-12-31
ZA200100232B (en)	2002-04-09
PL345897A1 (en)	2002-01-14
SK312001A3 (en)	2001-06-11
WO2000002543A2 (fr)	2000-01-20
AU5034999A (en)	2000-02-01
EP1870098A2 (fr)	2007-12-26
NZ509260A (en)	2003-09-26
CZ304359B6 (cs)	2014-03-26
DK1096932T3 (da)	2007-10-15
RU2012110522A (ru)	2013-09-27
CY1107779T1 (el)	2010-07-28
NL300800I2 (fr)	2016-07-27
NO2012013I2 (no)	2014-10-27
CY2007026I2 (el)	2009-11-04
ES2552639T3 (es)	2015-12-01
HU229383B1 (en)	2013-11-28
HUP0102828A3 (en)	2002-11-28

Legal Events

Date

Code

Title

Description

2010-06-07

SPCF

Filing of an spc

Free format text: PRODUCT NAME: VALSARTAN, AMLODIPIN A HYDROCHLOROTIAZID; NAT. REGISTRATION NO/DATE: EU/1/09/569/001 - EU/1/09/569/060 20091016; FIRST REGISTRATION: CH 59407 01 - 59407 05 20090916

Spc suppl protection certif: 5006-2010

Filing date: 20100413

2018-11-05

MG4A

Partial revocation of patent

Effective date: 20180628

2019-09-03

MK4A

Patent expired

Expiry date: 20190709

Publication	Publication Date	Title
SK312001A3 (en)	2001-06-11	Antihypersensitive combination of valsartan and calcium channel blocker
US6395728B2 (en)	2002-05-28	Method of treatment and pharmaceutical composition
US6204281B1 (en)	2001-03-20	Method of treatment and pharmaceutical composition
US6162802A (en)	2000-12-19	Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
US20040266836A1 (en)	2004-12-30	Organic compounds
US5527801A (en)	1996-06-18	Ameliorant for blood lipid metabolism
AU2003200032B2 (en)	2006-03-02	Method of treatment and pharmaceutical composition
WO2005039637A2 (fr)	2005-05-06	Combinaisons
MXPA01000322A (en)	2001-09-07	Method of treatment and pharmaceutical composition
HK1152897B (en)	2016-02-26	Combined use of valsartan and calcium channel blockers for therapeutic purposes
HK1085659A (en)	2006-09-01	Antihypersensitive combination of valsartan and calcium channel blocker
HK1036758B (en)	2008-07-18	Antihypertensive combination of valsartan and calcium channel blocker